| Literature DB >> 22415608 |
Lise Vilstrup Holm1, Dorte Gilså Hansen, Christoffer Johansen, Peter Vedsted, Pia Veldt Larsen, Jakob Kragstrup, Jens Søndergaard.
Abstract
PURPOSE: To investigate associations between cancer survivors' sex, age, and diagnosis in relation to their (1) need for rehabilitation, (2) participation in rehabilitation activities, and (3) unmet needs for rehabilitation in a 14-month period following date of diagnosis.Entities:
Mesh:
Year: 2012 PMID: 22415608 PMCID: PMC3461205 DOI: 10.1007/s00520-012-1420-0
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.603
Fig. 1Inclusion of patients into the study
Medical and demographic characteristics of responders and non-responders in a cohort study of cancer rehabilitation
| Responders, | Non-responders, | |
|---|---|---|
| 3,439 (69.5) | 1,508 (30.5) | |
| Sex | ||
| Men | 1,466 (42.6) | 712 (47.2) |
| Women | 1,973 (57.4) | 796 (52.8) |
| Age (years) | ||
| 18–39 | 152 (4.4) | 118 (7.8) |
| 40–49 | 331 (9.6) | 154 (10.2) |
| 50–59 | 660 (19.2) | 292 (19.4) |
| 60–69 | 1,263 (36.8) | 419 (27.8) |
| 70–79 | 802 (23.3) | 338 (22.4) |
| 80+ | 231 (6.7) | 187 (12.4) |
| Cancer diagnoses | ||
| Breast | 976 (28.4) | 314 (20.8) |
| Prostate | 501 (14.6) | 179 (11.9) |
| Colo-rectal | 522 (15.2) | 213 (14.1) |
| Gynecological | 230 (6.7) | 120 (7.9) |
| Malignant melanoma | 233 (6.8) | 102 (6.8) |
| Lung | 188 (5.5) | 113 (7.5) |
| Lymphoma | 104 (3.0) | 44 (2.9) |
| Head and neck | 125 (3.6) | 81 (5.4) |
| Other | 560 (16.2) | 342 (22.7) |
Needs for rehabilitation during 14 months following time of diagnosis
| Physical area | Emotional area | Family oriented area | Sexual area | Work-related area | Financial area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| ||||||||||||||
|
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | Men | Women |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) | |
| Needs, total | 1,028 (31.7) | − | − | 997 (30.6) | − | − | 453 (13.9) | − | − | 529 (16.6) | − | − | − | 252 (19.8) | − | − | 257 (13.4) | − | − |
| Sex | |||||||||||||||||||
| Men | 352 (25.4) | 1.00 | 1.00 | 327 (23.5) | 1.00 | 1.00 | 145 (10.4) | 1.00 | 1.00 | 308 (22.5) | 1.00 | − | − | 77 (14.3) | 1.00 | 1.00 | 118 (13.8) | 1.00 | 1.00 |
| Women | 676 (36.5) | 1.69** | 1.36** (1.01–1.70) | 670 (35.9) | 1.82** | 1.72** (1.37–2.17) | 308 (16.6) | 1.70** | 1.40* (1.04–1.88) | 221 (12.1) | 0.47** | − | − | 175 (23.7) | 1.87** | 1.55* (1.01–2.39) | 139 (13.4) | 0.97 | 0.86 (0.60–1.25) |
| Age (years) | |||||||||||||||||||
| 18–39 | 54 (36.0) | 1.00 | 1.00 | 82 (54.3) | 1.00 | 1.00 | 47 (31.3) | 1.00 | 1.00 | 34 (22.5) | 1.00 | 1.00 | 1.00 | 23 (22.3) | 1.00 | 1.00 | 20 (16.7) | 1.00 | 1.00 |
| 40–49 | 149 (46.4) | 1.54* | 1.35 (0.90–2.03) | 176 (53.8) | 0.98 | 0.86 (0.57–1.28) | 96 (29.3) | 0.91 | 0.82 (0.53–1.27) | 77 (23.7) | 1.07 | 0.83 (0.35–2.02) | 0.91 (0.51–1.62) | 73 (32.0) | 1.64 | 1.43 (0.82–2.51) | 51 (19.5) | 1.21 | 1.33 (0.74–2.38) |
| 50–59 | 263 (41.3) | 1.25 | 1.13 (0.77–1.65) | 279 (43.8) | 0.66* | 0.59** (0.40–0.85) | 135 (21.2) | 0.59** | 0.55** (0.36–0.83) | 133 (21.0) | 0.91 | 0.93 (0.43–1.99) | 0.61 (0.35–1.06) | 116 (28.9) | 1.41 | 1.27 (0.74–2.17) | 97 (19.5) | 1.21 | 1.31 (0.76–2.27) |
| 60–69 | 339 (27.8) | 0.68* | 0.63* (0.43–0.91) | 304 (25.0) | 0.28** | 0.25** (0.17–0.36) | 117 (9.6) | 0.23** | 0.22** (0.14–0.33) | 203 (17.0) | 0.71 | 0.72 (0.34–1.51) | 0.25** (0.14–0.44) | 32 (9.8) | 0.38** | 0.37** (0.20–0.69) | 66 (10.8) | 0.61 | 0.65 (0.37–1.15) |
| 70–79 | 172 (23.6) | 0.55** | 0.53** (0.36–0.78) | 125 (17.0) | 0.17** | 0.16** (0.11–0.24) | 48 (6.6) | 0.15** | 0.15** (0.09–0.24) | 69 (9.7) | 0.37** | 0.33** (0.15–0.72) | 0.04** (0.01–0.11) | 6 (3.6) | 0.13** | 0.12** (0.05–0.32) | 18 (5.6) | 0.30** | 0.30** (0.15–0.61) |
| 80+ | 51 (27.4) | 0.67 | 0.64 (0.39–1.03) | 31 (16.4) | 0.17** | 0.15** (0.09–0.26) | 10 (5.3) | 0.12** | 0.12** (0.06–0.25) | 13 (7.1) | 0.26** | 0.26** (0.10–0.69) | 0.06** (0.01–0.26) | 2 (4.0) | 0.14* | 0.14* (0.03–0.63) | 5 (6.0) | 0.32* | 0.35 (0.12–1.00) |
| Cancer diagnosis | |||||||||||||||||||
| Breast | 367 (39.5) | 1.00 | 1.00 | 338 (36.2) | 1.00 | 1.00 | 152 (16.3) | 1.00 | 1.00 | 111 (12.1) | 1.00 | − | 1.00 | 94 (23.9) | 1.00 | 1.00 | 62 (11.7) | 1.00 | 1.00 |
| Prostate | 96 (20.7) | 0.40** | 0.70* (0.50–0.99) | 89 (19.1) | 0.42** | 1.16 (0.80–1.66) | 30 (6.4) | 0.35** | 0.85 (0.51–1.43) | 159 (34.3) | 3.79** | 2.44** (1.67–3.56) | − | 15 (9.7) | 0.34** | 1.11 (0.52–2.36) | 22 (8.2) | 0.67 | 0.93 (0.49–1.78) |
| Colo-rectal | 142 (29.0) | 0.62** | 0.84 (0.65–1.10) | 109 (22.2) | 0.51* | 0.88 (0.66–1.18) | 50 (10.2) | 0.58** | 0.96 (0.66–1.41) | 68 (14.2) | 1.20 | 1.00 | 1.11 (0.65–1.89) | 31 (16.8) | 0.64 | 1.17 (0.69–1.98) | 32 (11.7) | 0.99 | 1.17 (0.70–1.96) |
| Gynecological | 69 (31.9) | 0.72* | 0.72* (0.52–0.99) | 79 (36.1) | 0.99 | 1.00 (0.72–1.38) | 43 (19.6) | 1.25 | 1.25 (0.85–1.85) | 41 (19.1) | 1.71** | − | 1.83** (1.21–2.77) | 26 (30.2) | 1.38 | 1.36 (0.80–2.32) | 22 (17.3) | 1.58 | 1.64 (0.96–2.82) |
| Malignant melanoma | 49 (22.4) | 0.44** | 0.48** (0.33–0.68) | 51 (23.2) | 0.53** | 0.52** (0.35–0.75) | 19 (8.6) | 0.49** | 0.43* (0.25–0.73) | 16 (7.3) | 0.57* | 0.34** (0.15–0.75) | 0.34** (0.16–0.75) | 8 (8.3) | 0.29** | 0.36* (0.16–0.80) | 13 (10.0) | 0.84 | 0.83 (0.43–1.62) |
| Lung | 71 (39.7) | 1.01 | 1.43* (1.01–2.04) | 70 (39.3) | 1.14 | 2.19** (1.52–3.16) | 28 (15.6) | 0.95 | 1.65* (1.03–2.66) | 27 (15.7) | 1.35 | 0.99 (0.53–1.84) | 1.53 (0.74–3.16) | 8 (15.7) | 0.59 | 1.09 (0.47–2.54) | 18 (17.1) | 1.56 | 2.00* (1.07–3.75) |
| Lymphoma | 35 (34.3) | 0.80 | 0.92 (0.59–1.44) | 49 (48.0) | 1.63* | 2.24 **(1.42–3.51) | 24 (23.8) | 1.60 | 1.90* (1.12–3.23) | 15 (15.0) | 1.28 | 0.87 (0.40–1.87) | 0.76 (0.29–2.02) | 9 (19.6) | 0.78 | 0.93 (0.41–2.10) | 11 (16.2) | 1.46 | 1.39 (0.67–2.91) |
| Head and neck | 32 (26.9) | 0.56** | 0.69 (0.43–1.09) | 39 (33.3) | 0.88 | 1.29 (0.82–2.04) | 15 (12.9) | 0.76 | 0.97 (0.52–1.80) | 12 (10.4) | 0.84 | 0.31** (0.13–0.72) | 1.49 (0.54–4.11) | 14 (25.5) | 1.09 | 1.57 (0.74–3.32) | 12 (15.0) | 1.33 | 1.20 (0.58–2.50) |
| Other | 167 (31.9) | 0.72** | 0.92 (0.70–1.20) | 173 (32.9) | 0.87 | 1.29 (0.98–1.70) | 92 (17.6) | 1.09 | 1.42* (1.01–2.02) | 80 (15.4) | 1.32 | 0.81 (0.52–1.25) | 1.07 (0.64–1.78) | 47 (22.5) | 0.93 | 1.38 (0.84–2.28) | 65 (20.8) | 1.99 | 2.03** (1.28–3.22) |
For each area (physical, emotional, family oriented, sexual, work-related, and financial) number, frequencies and crude and adjusted odds ratios (ORs) are shown with regard to sex, age, and cancer diagnosis
aAdjusted for sex, age group, and cancer diagnosis
bAdjusted for age group and cancer diagnosis
*p < 0.05
**p < 0.01
Participation in rehabilitation activities during 14 months following time of diagnosis
| One or more activities | One or more physical activities | One or more psychological activities | One or more work-related/financial activities | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
| |||||||||
|
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) | |
| Participation, total | 1,697 (52.1) | − | − | 1,447 (42.1) | − | − | 586 (17.0) | − | − | 403 (11.7) | − | − |
| Sex | ||||||||||||
| Men | 545 (39.4) | 1.00 | 1.00 | 438 (29.9) | 1.00 | 1.00 | 152 (10.4) | 1.00 | 1.00 | 134 (9.1) | 1.00 | 1.00 |
| Women | 1,152 (61.5) | 2.46** | 1.54** (1.25–1.90) | 1009 (51.1) | 2.46** | 1.41** (1.14–1.73) | 434 (22.0) | 2.44** | 1.90** (1.43–2.52) | 269 (13.6) | 1.56** | 1.03 (0.74–1.43) |
| Age (years) | ||||||||||||
| 18–39 | 102 (67.1) | 1.00 | 1.00 | 68 (44.7) | 1.00 | 1.00 | 63 (41.5) | 1.00 | 1.00 | 55 (36.2) | 1.00 | 1.00 |
| 40–49 | 234 (72.2) | 1.27 | 0.88 (0.57–1.37) | 197 (59.5) | 1.82** | 1.29 (0.85–1.96) | 118 (35.6) | 0.78 | 0.59* (0.39–0.89) | 87 (26.3) | 0.63* | 0.50** (0.32–0.78) |
| 50–59 | 443 (69.7) | 1.13 | 0.81 (0.54–1.22) | 344 (52.1) | 1.34 | 1.02 (0.70–1.50) | 184 (27.9) | 0.55** | 0.42** (0.29–0.63) | 163 (24.7) | 0.58** | 0.48** (0.32–0.72) |
| 60–69 | 600 (49.6) | 0.48** | 0.34** (0.23–0.51) | 546 (43.2) | 0.94 | 0.74 (0.51–1.08) | 154 (12.2) | 0.20** | 0.16** (0.11–0.24) | 71 (5.6) | 0.11** | 0.09** (0.06–0.13) |
| 70–79 | 257 (34.7) | 0.26** | 0.21** (0.14–0.32) | 238 (29.7) | 0.52** | 0.48** (0.33–0.71) | 53 (6.6) | 0.10** | 0.09** (0.06–0.14) | 19 (2.4) | 0.04** | 0.04** (0.02–0.07) |
| 80+ | 61 (31.4) | 0.22** | 0.18** (0.11–0.29) | 54 (23.4) | 0.38** | 0.34** (0.21–0.55) | 14 (6.1) | 0.10** | 0.08** (0.04–0.15) | 8 (3.5) | 0.06** | 0.05** (0.02–0.12) |
| Cancer diagnosis | ||||||||||||
| Breast | 694 (73.9) | 1.00 | 1.00 | 652 (66.8) | 1.00 | 1.00 | 239 (24.5) | 1.00 | 1.00 | 152 (15.6) | 1.00 | 1.00 |
| Prostate | 163 (35.0) | 0.19** | 0.41** (0.30–0.57) | 139 (27.7) | 0.19** | 0.34** (0.25–0.47) | 34 (6.8) | 0.22** | 0.77 (0.47–1.24) | 23 (4.6) | 0.26** | 0.65 (0.36–1.17) |
| Colo-rectal | 192 (39.8) | 0.23** | 0.36** (0.27–0.47) | 149 (28.5) | 0.20** | 0.28** (0.22–0.36) | 70 (13.4) | 0.48** | 0.91 (0.65–1.27) | 47 (9.0) | 0.54** | 0.84 (0.56–1.27) |
| Gynecological | 107 (47.8) | 0.32** | 0.31** (0.23–0.42) | 78 (33.9) | 0.26** | 0.25** (0.19–0.34) | 47 (20.4) | 0.79 | 0.76 (0.53–1.11) | 30 (13.0) | 0.81 | 0.77 (0.49–1.21) |
| Malignant melanoma | 71 (32.3) | 0.17** | 0.16** (0.11–0.22) | 52 (22.3) | 0.14** | 0.16** (0.11–0.22) | 25 (10.7) | 0.37** | 0.32** (0.20–0.52) | 12 (5.2) | 0.29** | 0.20** (0.10–0.38) |
| Lung | 93 (52.0) | 0.38** | 0.62** (0.43–0.89) | 75 (39.9) | 0.33** | 0.46** (0.33–0.65) | 31 (16.5) | 0.61* | 1.22 (0.78–1.92) | 15 (8.0) | 0.47** | 0.82 (0.44–1.50) |
| Lymphoma | 54 (54.0) | 0.41** | 0.47** (0.30–0.74) | 45 (43.3) | 0.38** | 0.44** (0.28–0.67) | 25 (24.0) | 0.98 | 1.24 (0.74–2.08) | 30 (28.9) | 2.20** | 2.36** (1.39–4.03) |
| Head and neck | 69 (58.5) | 0.50* | 0.65 (0.42–1.01) | 54 (43.2) | 0.38** | 0.49** (0.32–0.74) | 27 (21.6) | 0.85 | 1.35 (0.81–2.25) | 11 (8.8) | 0.52* | 0.49* (0.24–0.99) |
| Other | 254 (48.0) | 0.33** | 0.44** (0.33–0.57) | 203 (36.3) | 0.28** | 0.37** (0.29–0.48) | 88 (15.7) | 0.57** | 0.83 (0.60–1.15) | 83 (14.8) | 0.94 | 1.01 (0.69–1.47) |
For each area (one or more activities, one or more physical activities, one or more psychological activities, and one of more work-related/financial activities) number, frequencies and crude and adjusted odds ratios (ORs) are shown with regard to sex, age, and cancer diagnosis
aAdjusted for sex, age group, and cancer diagnosis
*p < 0.05
**p < 0.01
Unmet needs for rehabilitation 14 months after diagnosis
| Physical area | Emotional area | Family oriented area | Sexual area | Work-related area | Financial area | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |||||||||||||
|
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) |
| ORcrude | ORadja (95% CI) | |
| Unmet needs, total | 159 (17.3) | − | − | 209 (23.7) | − | − | 122 (32.1) | − | − | 225 (49.6) | − | − | 43 (18.7) | − | − | 79 (34.4) | − | − |
| Sex | ||||||||||||||||||
| Men | 63 (19.8) | 1.00 | 1.00 | 85 (31.1) | 1.00 | 1.00 | 43 (34.4) | 1.00 | 1.00 | 124 (46.8) | 1.00 | 1.00 | 18 (26.1) | 1.00 | 1.00 | 42 (39.3) | 1.00 | 1.00 |
| Women | 96 (15.9) | 0.76 | 0.96 (0.60–1.54) | 124 (20.3) | 0.56** | 0.58** (0.37–0.92) | 79 (31.0) | 0.86 | 1.06 (0.58–1.93) | 101 (53.4) | 1.31 | 0.80 (0.42–1.55) | 25 (15.5) | 0.52 | 0.53 (0.19–1.47) | 37 (30.1) | 0.67 | 0.53 (0.24–1.19) |
| Age (years) | ||||||||||||||||||
| <60 | 64 (15.3) | 1.00 | 1.00 | 91 (18.3) | 1.00 | 1.00 | 65 (26.9) | 1.00 | 1.00 | 105 (47.7) | 1.00 | 1.00 | 33 (16.6) | 1.00 | 1.00 | 53 (33.3) | 1.00 | 1.00 |
| ≥60 | 95 (18.9) | 1.29 | 1.17 (0.81–1.70) | 118 (30.7) | 1.98** | 2.05** (1.47–2.85) | 57 (41.3) | 1.92** | 2.03** (1.27–3.25) | 120 (51.3) | 1.15 | 1.83** (1.16–2.89) | 10 (32.3) | 2.40* | 2.98* (1.14–7.80) | 26 (36.6) | 1.16 | 1.08 (0.58–2.03) |
| Cancer diagnosis | ||||||||||||||||||
| Breast | 40 (12.1) | 1.00 | 1.00 | 55 (17.7) | 1.00 | 1.00 | 33 (26.4) | 1.00 | 1.00 | 54 (56.8) | 1.00 | 1.00 | 12 (14.1) | 1.00 | 1.00 | 19 (38.0) | 1.00 | 1.00 |
| Prostate | 16 (18.4) | 1.63 | 1.46 (0.65–3.27) | 24 (30.8) | 2.06* | 0.94 (0.45–1.97) | 7 (28.0) | 1.08 | 0.83 (0.26–2.62) | 51 (36.4) | 0.44** | 0.24** (0.10–0.56) | 2 (15.4) | 1.11 | 0.30 (0.04–2.35) | 10 (55.6) | 2.04 | 1.06 (0.27–4.13) |
| Colo-rectal | 28 (22.1) | 2.05** | 1.93* (1.07–3.48) | 18 (19.6) | 1.13 | 0.78 (0.41–1.49) | 16 (38.1) | 1.72 | 1.62 (0.72–3.68) | 29 (48.3) | 0.71 | 0.52 (0.23–1.17) | 4 (14.8) | 1.06 | 0.55 (0.13–2.36) | 6 (23.1) | 0.49 | 0.32 (0.09–1.08) |
| Gynecological | 14 (24.6) | 2.36* | 2.33* (1.17–4.65) | 17 (23.9) | 1.46 | 1.47 (0.79–2.74) | 10 (30.3) | 1.21 | 1.16 (0.49–2.72) | 16 (48.5) | 0.71 | 0.68 (0.30–1.52) | 5 (19.2) | 1.45 | 1.45 (0.45–4.62) | 6 (28.6) | 0.65 | 0.65 (0.21–1.96) |
| Malignant melanoma | 4 (9.8) | 0.78 | 0.75 (0.25–2.26) | 17 (37.8) | 2.81** | 2.51* (1.24–5.05) | 5 (31.3) | 1.27 | 1.29 (0.40–4.13) | 8 (72.7) | 2.02 | 1.68 (0.40–6.99) | 0 (0) | − | − | 3 (23.1) | 0.49 | 0.31 (0.07–1.46) |
| Lung | 15 (22.7) | 2.13* | 1.97 (0.97–4.01) | 16 (28.6) | 1.85 | 1.31 (0.66–2.60) | 10 (40.0) | 1.86 | 1.46 (0.57–3.72) | 14 (66.7) | 1.52 | 1.13 (0.39–3.27) | 4 (50.0) | 6.08* | 4.02 (0.75–21.7) | 7 (43.8) | 1.27 | 0.86 (0.25–3.02) |
| Lymphoma | 7 (21.9) | 2.03 | 1.95 (0.76–5.00) | 15 (34.1) | 2.39* | 2.05 (0.99–4.27) | 9 (40.9) | 1.93 | 2.19 (0.81–5.89) | 8 (53.3) | 0.87 | 0.72 (0.22–2.36) | 2 (22.2) | 1.74 | 1.65 (0.29–9.26) | 4 (36.4) | 0.93 | 0.69 (0.17–2.88) |
| Head and neck | 9 (32.1) | 3.43** | 3.32** (1.34–8.22) | 13 (35.1) | 2.51* | 2.00 (0.90–4.43) | 6 (42.9) | 2.09 | 2.09 (0.64–6.85) | 7 (63.6) | 1.33 | 1.24 (0.32–4.81) | 4 (28.6) | 2.43 | 1.63 (0.36–7.29) | 6 (50.0) | 1.63 | 0.97 (0.23–4.10) |
| Other | 26 (16.9) | 1.47 | 1.41 (0.77–2.57) | 34 (22.7) | 1.36 | 0.98 (0.56–1.72) | 26 (33.3) | 1.39 | 1.48 (0.72–3.04) | 38 (55.9) | 0.96 | 0.77 (0.35–1.69) | 10 (25.0) | 2.03 | 1.25 (0.39–4.05) | 18 (28.6) | 0.65 | 0.43 (0.16–1.13) |
For each area (physical, emotional, family oriented, sexual, work-related, and financial) number, frequencies and crude and adjusted odds ratios (ORs) are shown with regard to sex, age, and cancer diagnosis.
aAdjusted for sex, age group, and cancer diagnosis
*p < 0.05
**p < 0.01